Key result
Among athletes with genetic heart diseases who returned to competitive sports, only 3% (9/322) experienced a nonlethal breakthrough cardiac event.
Why the study?
Does return-to-play after shared decision-making and comprehensive treatment lead to breakthrough cardiac events in athletes with genetic heart diseases?
Observational (n=366)
No
Does return-to-play after shared decision-making and comprehensive treatment lead to breakthrough cardiac events in athletes with genetic heart diseases?
Athletes with genetic heart diseases can safely return to competitive sports after shared decision-making and comprehensive treatment, with a very low rate of breakthrough cardiac events.
Answers are grounded in this paper and cite their sources.
May support shared decision-making for selected athletes with HCM or LQTS; leaves open need for prospective trials to confirm safety.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Turkowski et al. (2018) conducted an observational in Genetic heart diseases (n=366). Return-to-play in competitive sports vs. Self-disqualification was evaluated on Nonlethal breakthrough cardiac event. Among athletes with genetic heart diseases who returned to competitive sports, only 3% (9/322) experienced a nonlethal breakthrough cardiac event.
Synapse has enriched 10 related papers. Consider them for comparative context: